Additional File 1. Clinical and biological characteristics of acute myeloid leukemia patients ___________________________________________________________________________________________________________________________

Valproic acid in combination with all-trans retinoic acid and intensive induction therapy for acute myeloid leukemia in older patients. Mechanism of action of

Myeloid neoplasms in pretreated patients with CLL are defined as late complication of cytotoxic chemotherapy or radiotherapy by WHO Classification of Hematologic malignancies

Numerous studies have established that an elevated plasma concentration of the amino acid homocysteine (Hcy) is an independent risk factor for cardiovaseular disease [1—3].In

Results of a phase 1 study of quizartinib (AC220) as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic cell

Relapse-free survival (RFS) and overall survival (OS) in patients positive for FMS-like tyrosine kinase 3 – internal tandem duplication acute myeloid leukemia in complete

The Rivaroxaban for Scheduled Work-up of Deep Vein Thrombosis Study (the Ri-Schedule study, www.clinicaltrials.gov identifier NCT02486445) was a prospective outcome trial

Panel B shows the between-group comparison of overall survival with stratification according to subtype of FLT3 mutation: point mutation in the tyrosine kinase domain (TKD)

Eligible patients aged 18 years or older with ECOG performance status 0–2 with relapsed or refractory (duration of first composite complete remission ≤6 months) FLT3-ITD acute